

**CENTER FOR DRUG EVALUATION AND  
RESEARCH**

*APPLICATION NUMBER:*

**022231Orig1s000**

**OFFICER/EMPLOYEE LIST**

MEMORANDUM

DEPARTMENT OF HEALTH AND HUMAN SERVICES  
PUBLIC HEALTH SERVICE  
FOOD AND DRUG ADMINISTRATION  
CENTER FOR DRUG EVALUATION AND RESEARCH

**DATE:** August 9, 2022

**TO:** Administrative file for NDA 22231

**FROM:** Anna Park, Regulatory Health Project Manager  
Division of Cardiology and Nephrology, Office of Regulatory Operations

**SUBJECT:** Officer/Employee List for NDA 22231

**APPLICATION/DRUG:** NDA 22231, TERLIVAZ (terlipressin)

The following officers or employees of FDA participated in the decision to approve this application and consented to be identified on this list:

**Last name, First name (alphabetize by last name)**

Adams, Grafton  
Aidoo, Mariette  
Ajao, Adebola  
Caruth, Brian  
Carver, Theodore  
Chi, Xuan  
Davis, Anissa  
Dexter, Paul  
Jagadessh, Gowra  
Kambhampati, Rekha  
Liedtka, Jane  
McDowell, Tzu-Yun  
Mehta, Hina  
Monteleone, Michael  
Park, Anna  
Sapru, Mohan  
Sathigari, Sateesh  
Southworth, Mary Ross  
Stockbridge, Norman  
Thompson, Aliza  
Woronow, Daniel  
Yanoff, Lisa  
Zhang, Jialu